Hemispherx Biopharma's Vaccine Enhancement Platform to be Presented at the Second International Conference on Influenza Vaccines for the World.

Researchers at Japanese National Institute of Infectious Diseases to Present New Data

VIENNA, Austria -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that its collaborative research partners in Japan, headed by Dr. Hideki Hasegawa, M.D., Ph.D., will present new data on augmentation of influenza vaccines using Hemispherx's Vaccine Enhancement Drug platform.

Influenza vaccines, both seasonal and avian flu-specific, share certain limitations which researchers hope may be overcome by vaccine-enhancing agents, such as Hemispherx's Ampligen[R], an experimental therapeutic. Two of the main limitations faced by influenza vaccines are: 1) Poor host immune response (especially in individuals over 60 years of age), including marginal immune response in humans that "wears off" quickly without periodic boosting by means of additional vaccine inoculations, and 2) Limited vaccine supplies that it may be feasible to augment by co-administering vaccine enhancers such as Ampligen[R].

Dr. Hasegawa's tests have involved animals treated by various routes with Ampligen[R] (intramuscular and intranasal) in an effort to abort the lethality of a strain of avian influenza, H5N1, which is now endemic in Asia.

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon[R] and the experimental drugs Ampligen[R], Alferon LDO and Oragens(TM). Alferon[R] is approved for a category of STD infection, and Ampligen[R] and Oragens(TM) represent experimental nucleic acids being developed for globally important diseases. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon[R] N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen[R], Alferon[R] LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon[R] do not imply that the product will ever be specifically approved commercially for these other treatment indications.